Future Clinical Trial to Optimize Semaglutide with Lifestyle for Childhood Obesity

The rapid emergence of highly effective obesity medications like Semaglutide has significantly impacted pediatric weight management. However, a critical question remains regarding the optimal role and intensity of health behavior and lifestyle treatment (HBLT) when combined with these medications for adolescents living with obesity.

While specific results are pending as this is a future study, this clinical trial is designed to determine if low-intensity HBLT can achieve comparable benefits to intensive HBLT (26+ hours) when combined with Semaglutide for adolescent obesity. The primary objective is to quantify the BMI reduction across different intervention arms, assessing if one approach leads to a significantly greater decrease or if they are equally effective. > The study specifically aims to determine if low-intensity HBLT combined with Semaglutide can be an equally effective alternative to intensive HBLT (26+ hours) for improving BMI, quality of life, and cardiometabolic health in adolescents with obesity. Secondary outcomes will include evaluating improvements in quality of life and cardiometabolic health markers, such as blood pressure and lipid profiles, as well as mitigating nutritional concerns across the different treatment groups. The findings are expected to provide clear, data-driven guidance on the optimal intensity of lifestyle intervention needed when Semaglutide is prescribed for youth.